Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Oct 05, 2026
TickeronGET DAILY SIGNALS
HeartBeam (BEAT) Stock: Analyst Targets Signal +714% Upside Potential

HeartBeam (BEAT) Stock: Analyst Targets Signal +714% Upside Potential

Key Takeaways

  • The $3.50 central target is the arithmetic mean of five verified analyst price targets, which range widely from $2.00 to $5.00.
  • With shares near $0.43, reaching $3.50 would require a gain of roughly 714%, a very large move.
  • HeartBeam is a pre-revenue medical technology company developing a cable-free, 3D electrocardiogram (ECG) platform that synthesizes a standard 12-lead ECG.
  • The strongest supports are FDA clearances, early commercial partnerships, and a 2026 strategic pivot toward licensing its ECG technology.
  • The biggest risks are the absence of revenue, ongoing cash burn and dilution, and a Nasdaq listing deficiency.

Breaking Down the Analyst Consensus

HeartBeam, Inc. (BEAT) carries a small number of active analyst ratings as a small-cap name. The $3.50 central target I reference here is simply the average of five current, verified price targets: Maxim Group at $2.00 (August 2026), H.C. Wainwright at $2.50 (May 2026), B. Riley Securities at $4.00 (March 2026), Roth MKM at $4.00 (April 2026), and Benchmark at $5.00 (August 2026). This lines up closely with the independent one-year estimates around $3.50 from providers such as Refinitiv and StockAnalysis.

The wide spread from $2.00 to $5.00 highlights real differences in views on how quickly HeartBeam can commercialize. One firm moved to a Hold rating without a target in April 2026, and several others have lowered targets over the past year amid delayed revenue and added dilution. Optimistic voices focus on the long-term potential of the 3D ECG technology and licensing approach, while others emphasize execution timelines and funding needs.

Where the Stock Stands Today and the Road Ahead

Shares closed near $0.43 in early October 2026, giving the company a market capitalization of roughly $24 million. Closing that gap to the $3.50 target would mean upside of about 714%, which is a substantial move by any measure. The 52-week range between approximately $0.36 and $4.00 shows both the room for recovery and the stock’s history of sharp swings, including a peak near $4.00 in December 2025 followed by a steady decline.

Any sustained advance would likely need HeartBeam to shift from a development-stage company to one generating recurring revenue. The firm has yet to report sales, so its current valuation rests entirely on the promise of its technology. Progress toward higher targets would hinge on successful product launches, new licensing agreements, and clearer signs of a path to profitability.

Factors That Could Support Higher Prices

Several elements back the more constructive case. FDA clearance arrived for the 3D ECG technology in December 2024 and for the 12-lead synthesis software in December 2025. In June 2026, management outlined a move toward licensing the platform to established partners such as ECG device makers, patch and Holter producers, and wearable companies. Early partnerships were noted with first-quarter 2026 results, and the company holds more than 20 patents. It also points to a sizable opportunity in a cardiac-monitoring market estimated at roughly $40 billion.

Key Risks That Could Limit Gains

Significant hurdles remain. HeartBeam is still pre-revenue with no sales reported through mid-2026, a trailing net loss near $20 million, and roughly $9 million in cash. An $11.5 million equity offering at $0.80 per share extended the runway but added dilution. The company also faces a Nasdaq continued-listing notice tied to its sub-$1 share price. Repeated target reductions from analysts reflect ongoing skepticism about revenue timing. Intense competition in cardiac monitoring means any delay in commercialization, further dilution, or regulatory issues could keep the stock well below the average target.

Technical Picture and Levels to Watch

Technically, the $4.00 mark from December 2025 represents the 52-week high and a major resistance zone well above current levels. On the downside, support sits near the September 2026 low of $0.36, while reclaiming $1.00 would mark an important psychological step before any move toward higher targets. Recent price action from the lows shows the stock’s capacity for quick, high-volume moves, though the longer-term trend remains downward.

What to Monitor Going Forward

Analyst targets generally look out about 12 months, though the broad $2.00–$5.00 range shows varying assumptions. Key items to follow include the next earnings update expected around mid-November 2026, any new commercialization or licensing news, updates on cash position and financing, progress on Nasdaq compliance, and further revisions to price targets. None of these developments assure the stock will reach $3.50.

Checking Signals with Tickeron Tools

I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

AI Daily Buy/Sell Signals for Timing

For a more dynamic perspective on volatile names like this, Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical factors. In my experience, the tool helps surface opportunities and manage risk more systematically than manual review alone, which can be useful when monitoring a stock with HeartBeam’s price history.

Overall View

The $3.50 central target for HeartBeam, Inc. (BEAT) represents the average of five analyst estimates between $2.00 and $5.00, well above the recent price near $0.43 and implying roughly 714% upside. The positive case draws from regulatory clearances, the licensing strategy, and market size, while risks center on zero revenue, cash use, dilution, and listing concerns. The wide target range captures genuine uncertainty around execution. Reaching that level will depend on milestones that have yet to be proven, and nothing is assured.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BEAT

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


Momentum Indicator for BEAT turns negative, indicating new downward trend

BEAT saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 81 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BEAT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

BEAT moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BEAT crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAT advanced for three days, in 171 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

BEAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.770) is normal, around the industry mean (4.523). P/E Ratio (-0.788) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (6.105).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. BEAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a wireless medical technology company, which focuses on the delivery of health information

Industry ServicestotheHealthIndustry

Industry
Medical Specialties
Address
2118 Walsh Avenue
Phone
+1 408 899-4443
Employees
16
Web
https://www.heartbeam.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.